Inari Medical, Inc. (NASDAQ:NARI) CFO Mitch C. Hill Sells 6,000 Shares

Inari Medical, Inc. (NASDAQ:NARI) CFO Mitch C. Hill sold 6,000 shares of Inari Medical stock in a transaction on Friday, April 12th. The shares were sold at an average price of $40.96, for a total transaction of $245,760.00. Following the completion of the transaction, the chief financial officer now directly owns 181,294 shares in the company, valued at $7,425,802.24. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Inari Medical Stock Down 0.3 %

Shares of Inari Medical stock traded down $0.11 on Wednesday, hitting $38.99. The company’s stock had a trading volume of 336,671 shares, compared to its average volume of 1,131,004. Inari Medical, Inc. has a 52-week low of $38.35 and a 52-week high of $71.85. The firm has a fifty day moving average price of $48.03 and a 200-day moving average price of $55.75. The company has a market capitalization of $2.26 billion, a P/E ratio of -1,316.67 and a beta of 0.84.

Inari Medical (NASDAQ:NARI) last released its earnings results on Wednesday, February 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.09). The firm had revenue of $132.10 million during the quarter, compared to analysts’ expectations of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. Inari Medical’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.11) earnings per share. As a group, analysts expect that Inari Medical, Inc. will post -0.39 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price objective on shares of Inari Medical in a research note on Wednesday, March 6th. Piper Sandler cut shares of Inari Medical from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $85.00 to $55.00 in a research note on Thursday, February 29th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $75.00 price target on shares of Inari Medical in a research note on Friday, April 12th. Finally, Truist Financial lowered their price target on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating on the stock in a research note on Friday, March 22nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $73.71.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in shares of Inari Medical by 13.0% during the 2nd quarter. BlackRock Inc. now owns 6,385,806 shares of the company’s stock worth $371,271,000 after acquiring an additional 733,738 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Inari Medical by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 5,038,292 shares of the company’s stock worth $327,086,000 after acquiring an additional 325,586 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Inari Medical by 46.8% during the 1st quarter. Wellington Management Group LLP now owns 4,626,607 shares of the company’s stock worth $419,355,000 after acquiring an additional 1,475,313 shares during the period. Capital International Investors increased its position in Inari Medical by 0.8% during the 1st quarter. Capital International Investors now owns 2,838,045 shares of the company’s stock worth $257,240,000 after purchasing an additional 22,159 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in Inari Medical by 12.0% during the 2nd quarter. Alliancebernstein L.P. now owns 2,305,171 shares of the company’s stock worth $134,023,000 after purchasing an additional 247,389 shares in the last quarter. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.